Additionally, humanized monoclonal anti-IL-13 antibody treatment has shown some promise in a subset of severe asthma patients (77) but has failed to meet primary efficacy endpoints in IPF clinical trials (78, 79). The gene discussed is IL13; the disease is idiopathic pulmonary fibrosis.